Participants are divided into two groups based on their blood test results. For those who do not have detectable tumor DNA in their blood, the study compares a 6-month course of capecitabine alone to a 3-month course of oxaliplatin combined with capecitabine. For those who do have detectable tumor DNA, the study compares a 6-month course of fluorouracil, irinotecan, oxaliplatin, and calcium folinate to a 6-month course of fluorouracil, oxaliplatin, and calcium folinate. Calcium folinate is a substance used to help the other medications work more effectively.

During the study, the effectiveness of these treatments is monitored by looking at disease-free survival, which is the length of time a patient lives without any signs or symptoms of the cancer returning. The study also tracks overall survival and any side effects caused by the medications, such as neurotoxicity, which is damage to the nerves that can cause issues like tingling or numbness. The course of the study involves receiving the assigned medication through pills or an intravenous infusion, which is a method of delivering medicine directly into a vein through a tube.

The purpose of this study is to find out whether giving chemotherapy before surgery, with or without the heated chemotherapy treatment during surgery, followed by additional chemotherapy after surgery, helps patients stay free from cancer for a longer time compared to standard treatment. The study will look at whether patients remain disease-free for 36 months after treatment. Patients will be divided into different groups by chance, similar to flipping a coin, and each group will receive a different treatment approach. Some will receive chemotherapy before surgery combined with the heated chemotherapy treatment, some will receive only chemotherapy before surgery, and others will receive standard treatment.

During the study, patients will undergo imaging tests such as CT scan or MRI to monitor their cancer, and blood samples will be collected to look for traces of cancer cells in the bloodstream. The treatment may last up to 24 weeks for some medications, and patients will be followed for several years to see how well the treatment works. The study will measure how long patients live without their cancer returning, how long they survive overall, whether the cancer comes back in the abdominal area specifically, what type of side effects occur, and how much the tumor shrinks in response to treatment before surgery.

The purpose of the study is to assess how well these treatments work in shrinking the tumor before surgery. Participants will receive either the standard treatment alone or the standard treatment combined with aspirin, metformin, or both. The study will help determine if adding these medications can improve the response of the tumor to treatment.

Participants in the study will undergo a series of treatments over a period of time, with regular monitoring to assess the tumor’s response. The study aims to find out if these additional treatments can lead to better outcomes, such as reducing the size of the tumor or improving the chances of successful surgery. The trial will also look at other factors like survival rates and quality of life for participants.

The treatment being tested is atezolizumab, which is given as an infusion, meaning it is administered directly into the bloodstream through a vein. This study will also include a comparison with a placebo, which is a substance with no active medication, to see how effective atezolizumab is on its own. The study will last for up to 12 months, during which participants will receive the treatment and have regular check-ups to monitor their health and the status of their cancer.

Participants in the study will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on whether atezolizumab can be a beneficial treatment option for patients with this specific type of colorectal cancer who are not suitable for standard chemotherapy. The results could potentially lead to new treatment options for these patients in the future.

The treatment plan includes several anti-cancer medications that work in different ways to fight cancer cells. These medications are capecitabine (taken as tablets by mouth), oxaliplatin (given through a vein as an infusion), fluorouracil (given through a vein), and irinotecan (given through a vein as an infusion). The specific combination of these medications will be determined based on the results of the blood tests.

Throughout the study, participants will have regular blood samples taken to check for signs of cancer using the liquid biopsy test. They will also have routine medical check-ups and imaging tests to monitor their health. The study will track how well patients do over time, particularly focusing on whether they remain cancer-free for two years after their surgery.

The purpose of the study is to see if RO7198457 (autogene cevumeran) can improve the time patients remain free from cancer after surgery, compared to watchful waiting. Participants in the study will be randomly assigned to receive either the treatment or to be in the watchful waiting group. The study will last for a period of time, during which participants will have regular check-ups to monitor their health and any changes in their cancer status.

Throughout the study, the main focus will be on measuring how long patients remain free from cancer, known as disease-free survival (DFS). Other aspects being observed include the time until cancer returns, overall survival, and any side effects from the treatment. The study aims to provide valuable information on whether RO7198457 (autogene cevumeran) can offer a better outcome for patients with this type of cancer.

The purpose of the study is to determine if a personalized treatment strategy, guided by a blood test called ctDNA (circulating tumor DNA), can improve outcomes for patients compared to the standard chemotherapy approach. The study will involve randomizing patients into different treatment groups based on their ctDNA results after surgery. Some patients will receive conventional chemotherapy, while others will receive a personalized treatment plan. The study will also include a group receiving a placebo to compare the effectiveness of the treatments.

Participants in the trial will undergo treatment for a maximum period of six months. The study will monitor the patients’ health and response to the treatments over time, with follow-ups to assess the long-term effects. The trial aims to provide valuable insights into the potential benefits of personalized treatment strategies for colon cancer patients, ultimately aiming to improve their quality of life and survival rates.